Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Frontiers in PharmacologyOpen Access

Efficacy and safety of nebulized drugs in the treatment of non-severe mycoplasma pneumoniae pneumonia in children - a network meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLi ZengHYHui YeQZQiu Zhang

Discussion

Loading...

Member takes

Overview

Network meta-analysis shows nebulized drugs improve treatment efficacy in children with mycoplasma pneumoniae pneumonia, indicating a potential adjuvant role.

Key Points

  • Nebulized drug adjuvants significantly improve treatment outcomes in children with non-severe mycoplasma pneumoniae pneumonia.
  • In a meta-analysis of 79 studies, nebulized budesonide plus terbutaline was found to be particularly effective.
  • The combination treatment achieved better pulmonary function without increasing adverse events among participants.
  • Higher-quality clinical studies are needed to address the limitations found in some of the included studies.

Cite This Study

Zeng et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477f3fahttps://doi.org/10.3389/fphar.2025.1587152
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical efficacy of azithromycin-budesonide combination therapy in pediatric Mycoplasma pneumoniae pneumonia2025
  2. 2Efficacy of systemic glucocorticoids in pediatric Mycoplasma pneumoniae infection2025
  3. 3Combination Therapy In Pediatric Bronchitis: Examining Mucolytic, Bronchodilator And Anti-Inflammatory Drug Effects On Secretion Management And Recovery Time2025
  4. 4Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients2025
  5. 5Efficacy of combination mucolytic therapy in acute bronchitis in children2025